Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Colorectal cancers (CRCs) display global hypomethylation and specific promoter DNA hypermethylation.
• A distinct subtype, the CpG-island methylator phenotype (CIMP), shows extensive promoter methylation patterns.
• The functional roles of most methylated genes in CRC initiation and progression remain unclear.

Purpose of the Study:

• To examine functional evidence linking specific methylated genes to colorectal cancer pathogenesis.
• To review the mechanisms driving promoter methylation in CRC.
• To summarize current clinical trials and propose strategies for DNA methyltransferase inhibitors in CRC treatment.

Main Methods:

• Review of functional evidence for methylated genes in CRC.
• Analysis of mechanisms underlying promoter methylation (genetic events, transcription factor binding, DNA damage).
• Summary of clinical trials involving DNA methyltransferase inhibitors for CRC.

Main Results:

• Specific methylated genes, particularly those in deregulated signaling pathways, contribute to CRC pathogenesis.
• Mechanisms include genetic alterations, altered transcription factor binding, and DNA damage.
• Clinical trials of DNA methyltransferase inhibitors show potential but require optimized strategies for efficacy.

Conclusions:

• Understanding specific methylated genes and their roles is crucial for CRC pathogenesis.
• Elucidating methylation mechanisms can inform targeted therapeutic approaches.
• Enhancing the efficacy of DNA methyltransferase inhibitors is a key goal for CRC treatment.